Effects of Tongluo Jiedu prescription on immune function and oxidative stress in patients with oral cancer
- PMID: 38898875
- PMCID: PMC11185403
- DOI: 10.12998/wjcc.v12.i17.3045
Effects of Tongluo Jiedu prescription on immune function and oxidative stress in patients with oral cancer
Abstract
Background: Oral cancer, which is caused by mucous membrane variation, represents a prevalent malignant tumor in the oral and maxillofacial region, posing a significant threat to patients' lives and safety. While surgical intervention stands as a cornerstone treatment for oral cancer patients, it carries the risk of incomplete treatment or high rates of postoperative recurrence. Hence, a multifaceted approach incorporating diverse treatment modalities is essential to enhance patient prognosis.
Aim: To analyze the application effect of Tongluo Jiedu prescription as adjuvant therapy and its influence on patient prognosis in patients with oral cancer.
Methods: Eighty oral cancer patients in our hospital were selected and divided into the observation group and control group by a random number table. The control group was treated with continuous arterial infusion chemotherapy of cisplatin and 5-fluorouracil. The observation group was additionally given Tongluo Jiadu prescription. The inflammatory stress level, peripheral blood T-cell subsets, and immune function of the two groups were subsequently observed. SPSS 21.0 was used for data analysis.
Results: The observation group demonstrated lower levels of interleukin-6 and C-reactive protein, and a higher level of tumor necrosis factor in comparison to the control group. After treatment, the immune function in the observation group was significantly better than in the control group.
Conclusion: Tongluo Jiedu prescription can improve the immune function and oxidative stress level of patients with oral cancer and accelerate the recovery process.
Keywords: Immune function; Oral cancer patients; Oxidative stress; Tongluo Jiedu prescription.
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Conflict of interest statement
Conflict-of-interest statement: All authors declare no conflict of interest.
References
-
- Huang SH, Hahn E, Chiosea SI, Xu ZY, Li JS, Shen L, O'Sullivan B. The role of adjuvant (chemo-)radiotherapy in oral cancers in the contemporary era. Oral Oncol. 2020;102:104563. - PubMed
-
- Wu CF, Huang CJ, Chang KP, Chen CM. Continuous intra-arterial infusion chemotherapy as a palliative treatment for oral squamous cell carcinoma in octogenarian or older patients. Oral Oncol. 2010;46:559–563. - PubMed
-
- Xie YL, Han F, Jin YH, Ding YB, Guo J, Ji DX, Zhang T, Chen XM, Shang HC. Organic Integration of Traditional Chinese and Western Medicines-Future of Clinical Practice Guidelines of Integrated Traditional Chinese and Western Medicines. Chin J Integr Med. 2024;30:359–365. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
